Icatibant
FDA-approved B2 medicines that block a signal for acute HAE (hereditary angioedema, dangerous swelling attacks).
What it's for
Icatibant is a synthetic decapeptide that antagonizes the bradykinin B2 receptors (lock-and-key landing spots on cells). It treats acute attacks of hereditary angioedema.
What it does for the body
It treats acute attacks of hereditary angioedema. Patients may self-administer under-the-skin doses under labeled guidance. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
By blocking B2 receptors (lock-and-key landing spots on cells), icatibant interrupts bradykinin-mediated widening of blood vessels and edema that cause HAE (hereditary angioedema, dangerous swelling attacks) swelling. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Icatibant has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Skin research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Icatibant — FDA.gov search
- ClinicalTrials.gov search: Icatibant — U.S. clinical trials registry
- Drugs@FDA search: Icatibant — FDA drug database (if approved)
- PubMed search: Icatibant — NCBI PubMed
- PubMed Central search: Icatibant — NCBI PMC